CDT Equity (NASDAQ:CDT) Trading Down 5.3% – What’s Next?

Shares of CDT Equity Inc. (NASDAQ:CDT) fell 5.3% on Tuesday . The stock traded as low as $0.81 and last traded at $0.8475. 468,261 shares were traded during mid-day trading, a decline of 82% from the average session volume of 2,621,073 shares. The stock had previously closed at $0.8950.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of CDT Equity in a research note on Friday, March 27th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, CDT Equity currently has a consensus rating of “Sell”.

CDT Equity Stock Down 5.0%

The stock has a market capitalization of $3.91 million, a P/E ratio of 0.00 and a beta of 1.44. The business has a fifty day moving average price of $3.39 and a 200-day moving average price of $21.91.

About CDT Equity

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.